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Abstract
Introduction: OSAS (obstructive sleep apnea syndrome) is deﬁned by recurrent episodes of
upper airway obstruction during sleep, causing multiple clinical consequences. Literature
review suggests that OSAS induces a spectrum of abnormalities in neural, hormonal and vascular
regulation that contribute to the development of ED (erectile dysfunction).
The aims of this study were to estimate the prevalence of ED in OSAS patients and evaluate
its determinants.
Methods: 62 patients from Hospital S. João Sleep Laboratory with newly diagnosed OSAS were
included in the study and answered the IIEF-5 (international index erectile function 5 item
version) questionnaire.
Results: The prevalence of ED in OSAS patients was 64.4%. Age and diabetes constituted
themselves as independent risk factors for more severe degrees of ED: OR = 1.226 (95% CI:
1.062--1.415) and OR= 31.205 (95% CI: 1.222--796.557), respectively. Compared with nonsmok-
ers, ex-smokers group revealed a positive association with ED: OR = 4.32 (95% CI: 1.09--17.11).
Hypertension and ACEI (angiotensin converting enzyme inhibitors) or ARB (angiotensin II recep-
tor blockers) therapy were also correlated to ED symptoms: OR = 3.25 (95% CI: 1.09--9.65) and
7.39 (95% CI: 1.52--35.99), respectively.
No association was found relating BMI (p = 0.254), alcoholic habits (p = 0.357), acute myocar-
dial infarction (p = 0.315), dyslipidemia (p = 0.239), metabolic syndrome (p = 0.215) and ED.
OSAS severity was not associated with ED in our sample.
Conclusions: The prevalence of ED in OSAS patients is high. ED determinants in our sample
were age and diabetes. Past smoking habits, hypertension and ACEI/ARB therapy also revealed
a statistically signiﬁcant association with ED.
© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
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Hipertensão
Disfunc¸ão erétil na síndrome de apneia obstrutiva do sono -- Prevalência e
determinantes
Resumo
Introduc¸ão: A SAOS (síndroma de apneia obstrutiva do sono) deﬁne-se pela ocorrência frequente
de obstruc¸ão da via aérea superior durante o sono, com múltiplas consequências clínicas. Estu-
dos anteriores sugerem que a SAOS provoca alterac¸ões na regulac¸ão neural, hormonal e vascular
que contribuem para o desenvolvimento de DE (disfunc¸ão erétil).
Este estudo tem como principais objetivos estimar a prevalência da DE numa amostra de
doentes com SAOS e avaliar os seus determinantes.
Métodos: Foram incluídos 62 doentes do Laboratório do Sono do Hospital S. João com diag-
nóstico recente de SAOS, que responderam ao questionário IIEF-5 (International Index Erectile
Function-5 Item version).
Resultados: A prevalência da DE em pacientes com SAOS foi de 64,4%. A idade e a dia-
betes constituíram fatores de risco independentes para graus avanc¸ados de DE: OR = 1,226
(IC 95%:1,062--1,415) e OR = 31,205 (IC 95%:1,222--796,557), respetivamente. Comparados com
pacientes fumadores, o grupo de pacientes ex-fumadores revelou associar-se à DE: OR = 4,32
(IC 95%:1,09--17,11). A hipertensão e o tratamento com IECAS (inibidores da enzima conver-
sora da angiotensina) ou ARA (antagonistas dos recetores da angiotensina) evidenciaram uma
associac¸ão com DE: OR = 3,25 (IC 95%:1,09--9,65) e 7,39 (IC 95%:1,52--35,99), respetivamente.
Não foi encontrada nenhuma relac¸ão no que diz respeito ao IMC (p = 0,254), hábitos alcoóli-
cos (p = 0,357), enfarte agudo do miocárdio (p = 0,315), dislipidemia (p = 0,239), síndrome
metabólico (p = 0,215) e DE.
A gravidade da SAOS não se encontra associada a DE na amostra estudada.
Conclusões: A prevalência da DE em doentes com SAOS é elevada. Os determinantes da DE na
amostra estudada foram a idade e a diabetes. Ex-fumadores, hipertensão e tratamento com
ACEI/ARB também revelaram uma associac¸ão estatisticamente signiﬁcativa com a DE.
© 2011 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
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Erectile dysfunction (ED) is deﬁned as the consistent inabil-
ity to obtain and/or maintain a penile erection which is
sufﬁcient to permit satisfactory sexual intercourse.1,2 The
prevalence of ED is estimated at 48% among Portuguese men
aged 40--69 years old.3
Obstructive sleep apnea syndrome (OSAS) is character-
ized by repetitive collapse of the upper airway due to the
laxity of pharyngeal dilator muscles4 during sleep.
OSAS affects 4% of men between 30 and 60 years,5 but
it is believed that the proportion of clinically diagnosed
OSAS is underestimated.6--8 This is one of the most impor-
tant medical conditions to have been identiﬁed in the last
50 years.9 It is related to increased morbidity and mortality
due to clinical complications such as hypertension,10 conges-
tive heart failure,11 acute myocardial infarction,12 stroke,13
diabetes,14 cognitive dysfunction15 and depression.16
In every REM sleep stage most men experience a sleep
related erection (SRE),17 an event that ensures functional
and morphological integrity to erectile tissue.18 In OSAS,
intermittent hypoxic events and sleep fragmentation limit
SRE, with serious consequences for erectile physiology.19--22
The literature review also deﬁnes hormonal,23--26 neural,27--30endothelial31--35 and psychogenic16 mechanisms to explain ED
complaints in OSAS.
OSAS and ED may also be connected through co-
morbidities such as hypertension and diabetes.21
b
a
iAs there are some inconsistencies in regard to the preva-
ence data,18 the main purpose of this study was to estimate
he prevalence of ED in a population of OSAS patients sent
o Hospital S. João for diagnosis and follow-up. Addition-
lly, clinical and demographic information was collected to
btain the ED determinants in our population.
ethods
tudy population
etween 28 September and 31 December 2010, all men
dmitted (n = 207) to S. João Hospital Sleep Laboratory for a
rst medical appointment because of suspected OSAS, were
nvited to participate in the present study. Each patient
eceived written information about the study, an Informed
onsent form and an IIEF-5 questionnaire for them to com-
lete.
Ninety-ﬁve patients returned the completed question-
aire, 33 patients were excluded after sleep study as they
id not present OSAS and one was excluded because of a
revious diagnosis of ED.Information about BMI, previous medical history (dia-
etes, hypertension, stroke, acute myocardial infarction)
nd usual pharmacological therapy was obtained from med-
cal ﬁles.
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This study was approved by S. João Hospital Ethics Com-
ittee.
IEF-5 (International Index Erectile dysfunction -- 5
tem version)
IEF-5 is a simple and useful questionnaire for screening
atients with ED.36 Designed as a simpliﬁed version of IIEF,
t consists of 5 questions regarding erectile function and
atisfaction37 (Appendix A). The possible scores for IIEF-5
ange from 5 to 25, and ED was classiﬁed into ﬁve cate-
ories based on the scores obtained: absent (22--25), mild
17--21), mild to moderate (12--16), moderate (8--11), and
evere (5--7).
It was validated to be used in Portuguese.38
olygraphic cardiorespiratory sleep study (PCSS)
SAS is deﬁned by the presence of at least 5 obstruc-
ive respiratory events (apneas, hypopneas or respiratory
ffort related arousals) per hour of sleep in association
ith daytime sleepiness, loud snoring, witnessed breathing
nterruptions or waking up due to gasping or choking.39 The
resence of 15 or more obstructive respiratory events in the
bsence of sleep related symptoms is also sufﬁcient for the
iagnosis.39
Polysomnography is routinely indicated for the diagnosis
f sleep related breathing disorders,39--42,44,43 but its use is
imited by high costs and waiting lists.45
An overnight PCSS is an alternative to Polysomnogra-
hy when there is high pre-test probability.39 PCSS is made
p of a portable monitor device46 that records oronasal
irﬂow (measured by nasal cannula), arterial oxygen satura-
ion (measured by ﬁnger pulse oximetry), pulse rate, upper
imb, abdominal and thoracic movements, body position and
noring.47
All participants underwent PCSS with ApneaLink®,
lphaScreen Pro®, EMBLETTA® or Stardust® devices, which
alculate the number of apneas (episodes of ≤20% of pre-
ious airﬂow with at least 10 s of duration) and hypopneas
episodes showing 20--50% of the previous airﬂow, with at
east 10 s of duration joined with a 4% dip in oxygen satu-
ation) per hour of estimated sleep time. It also provides
nformation on desaturations >4% per hour of estimated
leep time (oxygen desaturation index).
Our analysis focused on apnea--hypopnea index (AHI),
xygen desaturation index (ODI), minimum and medium oxy-
en saturation.
According to established criteria,39 the severity OSAS was
tratiﬁed according to AHI value: mild (5--15), moderate
16--29) and severe (≥30).
tatistical analysis
ata analysis was performed with SPSS® (Statistical Package
or Social Sciences), 18.0 version.A frequency analysis was used to describe the population.
he Chi-square test was used to determine the association
etween categorical variables and Kruskall--Wallis test to
eﬁne any association between continuous and categorical
H
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ariables. Multivariate logistic regression was used to eval-
ate the effect of each variable adjusted to other possible
onfounding factors.
Every association with p < 0.05 was considered statisti-
ally signiﬁcant.
esults
he general characteristics of the population are described
n Table 1. The mean age was 52 years. Of 62 patients stud-
ed, 28 (45.1%) were obese, 23 (37.1%) had dyslipidemia,
1 (17.7%) metabolic syndrome (MS), 36 (58.1%) arterial
ypertension, 10 (16.1%) diabetes and 4 (6.5%) heart fail-
re. Previous acute myocardial infarction, stroke and pelvic
urgery were identiﬁed in 2 (3.2%), 6 (9.7%) and 2 (3.2%)
articipants, respectively. Mild OSAS was diagnosed in 30
48.4%), moderate OSAS in 14 (22.6%) and severe OSAS in
7 (27.4%) individuals. The ED prevalence was 64.4%, it was
ild in 24 (38.7%), mild to moderate in 12 (19.3%), moderate
n 1 (1.6%) and severe in 3 (4.8%) participants.
Univariate analysis results are shown in Table 2. Aging
as found to be signiﬁcantly related to ED: OR (95% CI) of
.90 (1.00--15.28); 5.50 (1.16--26.14); and 6.00 (1.00--35.91)
n categories 46--55, 56--65 and >65 years, respectively.
ast smoking habits were associated with ED (OR 4.32
1.09--17.11). Hypertension and ACEI (Angiotensin Convert-
ng Enzyme Inhibitors) or ARB (Angiotensin II Receptor
lockers) therapy revealed a statistically signiﬁcant associ-
tion with ED (OR 3.25 (1.09--9.65) and 7.39 (1.52--35.99)).
No association was found between dyslipidemia
p = 0.239), metabolic syndrome (p = 0.215), chronic
herapy with beta blockers (p = 0.217), calcium antagonists
p = 0.827) and serotonin-selective reuptake inhibitors
p = 0.250) and ED.
All patients with diabetes, stroke, cardiac failure and
revious pelvic surgery referred to ED on questionnaire, so
t was not possible to calculate odds ratio (OR) for these
ariables.
PCSS parameter analysis is described in Table 3. No asso-
iation was veriﬁed between ED and OSAS severity measured
y ODI, minimum and medium oxygen saturation and AHI
p = 0.494, p = 0.657, p = 0.498 and p = 0.403, respectively).
Multivariate analysis results are shown in Table 4. Age
nd diabetes were independent risk factors for more severe
egrees of ED: OR (95% CI) of 1.226 (1.062--1.415) and 31.205
1.222--796.557), respectively. There was no evidence that
MI (p = 932), smoking habits (p = 853), alcohol consump-
ion (p = 0.683), hypertension (p = 0.077) and OSAS severity
p = 0.661) were independent risk factors for ED.
iscussion
n 1981, Schmidt and Wise were the ﬁrst to describe a
elationship between ED and sleep disorders.48 After that,
everal studies conﬁrmed the increased prevalence of ED in
SAS patients51--54: Guilleminault et al. reported ejaculatory
ysfunction and decreased libido in 48% men with OSAS49;
irshkowitz et al. veriﬁed that 91.3% patients with ED symp-
oms also had OSAS50; Seftel et al. concluded that 40% OSAS
atients had ED.51 However, the association was rejected by
chiavi et al.52 In the present study, a 64.4% ED prevalence
Erectile dysfunction in obstructive sleep apnea syndrome----Prevalence and determinants 67
Table 1 Population general description (n = 62).
Variables Frequencies
Age
Mean (years) 52.16
≤45 20 (32.3%)
46--55 18 (29%)
56--65 14 (22%)
>65 10 (16%)
BMI
Mean 29.69
20--24.9 11 (17.7%)
25--29.9 23 (37.1%)
30--34.9 19 (30.6%)
>35 9 (14.5%)
Smoking habits
Current 18 (29%)
Pack-years (mean) 25.16
Past 23 (37.1%)
Pack-years (mean) 34.12
Nonsmokers 21 (33.9%)
Alcohol consumption
Absent 29 (46.8%)
≤60 g/day 23 (37.1%)
>60 g/day 10 (16.1%)
Comorbidities
Dyslipidemia 23 (37.1%)
Hypertension 36 (58.1%)
Diabetes 10 (16.1%)
Metabolic syndrome 11 (17.7%)
Heart failure 4 (6.5%)
Medical history
Stroke 2 (3.2%)
Myocardial infarction 6 (9.7%)
Pelvic surgery 2 (3.2%)
OSAS severity
Mild 30 (48.4%)
Moderate 14 (22.6%)
Severe 17 (27.4%)
Erectile dysfunction
Absent 22 (35.5%)
Mild 24 (38.7%)
Mild to moderate 12 (19.3%)
Moderate 1 (1.6%)
Severe 3 (4.8%)
BMI (body mass index); OSAS (obstructive sleep apnea syn-
Table 2 ED prevalence and association with clinical and
demographic variables.
Variable ED (%)a OR (95% CI)b p
Age
≤45 40.0 1 0.011
46--55 72.5 3.90 (1.00--15.28)
56--65 78.6 5.50 (1.16--26.14)
>65 80 6.00 (1.00--35.91)
BMI
20--24.9 63.6 1 0.254
25--29.9 78.3 2.06 (0.42--9.97)
30--34.9 52.6 0.64 (0.14--2.91)
>35 55.6 0.71 (0.12--4.32)
OSAS severity
Mild 66.7 1 0.723
Moderate 50.0 0.50 (0.14--1.82)
Severe 76.5 1.63 (0.42--6.29)
Metabolic syndrome
Absent 60.4 2.4 (0.59--9.76) 0.215
Present 78.6
Hypertension
Absent 48.0 3.25 (1.09--9.65) 0.032
Present 75.0
Dyslipidemia
Absent 59.0 1.97 (0.64--6.09) 0.239
Present 73.9
Myocardial infarction
Absent 62.5 3.00 (0.32--27.46) 0.215
Present 83.3
Alcohol consumption
Absent 69.0 1 0.357
≤60 g/day 65.2 0.84 (0.26--2.70)
>60 g/day 50.0 0.45 (0.10--1.95)
Smoking habits
Nonsmokers 52.4 1 0.719
Past 82.6 4.32 (1.09--17.11)
Current 55.6 1.14 (0.32--4.02)
ACEI/ARA therapy
Absent 53.5 7.39 (1.52--35.99) 0.007
Present 89.5
a Erectile dysfunction (ED): IIEF≤ 21.
b 95% conﬁdence interval.
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ddrome); ED (erectile dysfunction) classiﬁcation: absent (IIEF-5
22--25); mild (IIEF-5 17--21); mild to moderate (IIEF-5 12--16);
moderate (IIEF-5 8--11); severe (IIEF-5 5--7).
was found, which is consistent with most published material
on the subject.
In our sample, ED was not associated with severity of
OSAS. However it can be seen that the group with severe
OSAS did have a higher ED prevalence (Table 2) and patients
who reported severe ED had the worst results in sleep
study (Table 3), which indicates that studies with higher
sample size are needed to support the association Margel
o
f
ﬁt al. concluded that ED is associated exclusively with
evere OSAS.53 Furthermore, trials evaluating OSAS treat-
ent found improvements in ED,54--58 which shows that
here may be an association between both disorders, which
s understandable given that patients on CPAP treatment
how decreased hypoxia, improved endothelial function,
ecreased blood pressure and sympathetic hyperactivity, all
f which can improve erectile function.
In this study, age proved to be an independent risk factor
or ED, as suggested by the literature.59 It was also con-
rmed that the risk of ED increases with aging. It is already
68 T. Santos et al.
Table 3 PCSS study parameter analysis according to ED severity.
ED ODI MinO2Sat MedO2Sat AHI
Absent
Median 13.3 81.0 94.6 16.3
Min--Max 1.8--85.0 63.0--94.0 91.0--96.7 8.2--48.8
Mild
Median 7.75 83.0 95.0 13.6
Min--Max 0.6--70.0 24.0--91.0 88.0--98.0 5.3--76.0
Mild to moderate
Median 13.20 82.0 94.0 30.0
Min--Max 1.4--67.2 22.0--92.0 77.0--97.0 6.3--91.0
Severe
Median 24.0 76.0 89.0 24.9
Min--Max 9.0--81.3 50.0--84.0 84.4--96.4 9.9--83.2
p 0.494 0.657 0.498 0.403
It was not possible to analyze the category ‘‘moderate DE’’ because it was composed only by one subject.
ED (erectile dysfunction) classiﬁcation: absent (IIEF-5 22--25); mild (IIEF-5 17--21); mild to moderate (IIEF-5 12--16); moderate (IIEF-5
8--11); severe (IIEF-5 5--7).
ODI (oxygen desaturation index); MinO2Sat (minimum O2 saturation); MedO2Sat (medium O2 saturation); AHI (apnea--hypopnea index);
Min--Max (minimum--maximum).
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tstablished that age has more impact on erectile function
han the severity of OSAS.60
In addition, the data conﬁrmed that Diabetes is an inde-
endent risk factor for ED. It can be seen that diabetic
atients have a 31 times higher risk for more severe ED,
hich is supported by the effect of hyperglycemia on penile
eurovascular structure.61
Arterial hypertension was associated with ED in the uni-
ariate analysis. However, an association with more severe
D was not conﬁrmed by the multivariate analysis. This dif-
erence is probably due to a confounding effect of diabetes,
uggested by the fact that 9 out of 10 diabetic patients also
uffered from hypertension (data not shown in tables).
An association between MS and ED was not found.
evertheless, it is possible that the classiﬁcation used
nderestimated the actual proportion of affected patients
ince it was based on patient report and did not include
riglycerides or cholesterol plasmatic measurements.62 As
marker of systemic endothelial dysfunction, dyslipidemia
ay be more prevalent in ED patients.63 Fibrats and Statins,
ipid-lowering drugs, can also induce ED as a side effect,64
hich was not observed in our sample.
c
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Table 4 Multivariate logistic regressiona on the association betw
Variable p
Agec 0.005
BMIc 0.932
Smoking habits (past and current) 0.853
Alcohol consumption 0.683
Diabetes 0.037
Hypertension 0.077
OSAS severity 0.661
OSAS (obstructive sleep apnea syndrome).
a Dependent variable was categorized as ‘‘absent and mild ED’’ and
b 95% conﬁdence interval.
c Analyzed as categorical variables.Similarly, this study did not prove an association between
MI and ED, with patients in BMI interval 25--29 report-
ng more symptoms than those included in higher BMI
ategories. This is probably related to the fact that the
MI interval 25--29 included older patients (43% patients
etween 56 and 65 years and 50% of patients older than 65
ears), compared to the other categories (data not shown
n tables). In our sample, aging is an important confounding
actor when analyzing BMI data.
Concerning smoking habits, only ex-smokers showed a
tatistically signiﬁcant association with ED, probably due to
he fact that this group reported having had heavier smok-
ng habits (34 pack-years), compared to current smokers
25 pack-years). In a recent cross-sectional study65 smok-
ng habits of more than 23 years or 20 cigarettes per day
ere signiﬁcantly associated with ED.
Regarding chronic medication, an association was found
etween ACEI/ARB and ED. In fact, anti-hypertensive
herapy is associated with adverse sexual effects, most
ommonly involving diuretics and beta-blockers.66 ACEI/ARB
ere the most frequently used drugs and its association with
D may be due to hypertension itself.
een some clinical variables and ED.
OR 95% CIb
1.226 1.062--1.415
0.989 0.759--1.287
1.136 0.293--4.407
0.994 0.964--1.024
31.205 1.222--796.557
10.453 0.776--140.760
1.580 0.204--12.233
‘‘mild to moderate to severe ED’’.
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This study has some strong points in its favor. We used
a validated instrument to diagnose ED in clinical settings,
which was designed by urologists, and so added a multidisci-
plinary approach to OSAS. Patients with co-morbidities were
not excluded, which made it possible to measure the impact
on erectile function. The effect of chronic medication was
also evaluated.
However, this study also has limitations. Although it was
a representative population for estimating prevalence, we
analyzed multiple clinical variables, some of them shared
by our small number of subjects, which may have prevented
us from establishing more statistical signiﬁcant associations.
The size of our sample did not lend itself to such extended
analysis. The study was small because there was a high
refusal rate for patient participation (54%), possibly related
to the embarrassment about describing such an intimate
subject.
For future research larger scale studies are needed to
be able to evaluate multiple clinical variables. Among the
extended co-morbidities inherent to OSAS it is extremely
important not to neglect complications such as ED. If we
can use a bio-psychosocial approach with our patients, it
will certainly have greater impact.
Conclusions
ED is very common among patients with OSAS and may be
under recognized because patients do not spontaneously
report the problem. Several factors are associated with ED
among patients with OSAS and those include age, diabetes,
past smoking habits, hypertension and ACEI/ARB therapy.
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Appendix A. Erectile function survey (IIEF-5 --
International Index of Erectile Function,
ﬁve-item version)
(1) How would you rate your level of conﬁdence in achieving
and maintaining an erection?
1. Too low/none
2. Low
3. Normal
4. High
5. Too high
1lence and determinants 69
2) When you achieve erection by sexual stimulation, how
often is that erection sufﬁciently ﬁrm for penetration?
1. Almost never/never
2. A few times (less than half of the times)
3. Sometimes (about half of the times)
4. Often (more than half of the times)
5. Almost every time/always
3) During sexual intercourse, how many times have you
managed to maintain an erection after penetration?
1. Almost never/never
2. A few times (less than half of the times)
3. Sometimes (about half of the times)
4. Often (more than half of the times)
5. Almost every time/always
4) During sexual intercourse, is it difﬁcult to maintain an
erection until the end of sexual activity?
1. Extremely difﬁcult
2. Very difﬁcult
3. Difﬁcult
4. Slightly difﬁcult
5. Not difﬁcult
5) When you try to have attempt sexual intercourse, how
often are you successful?
1. Almost never/never
2. A few times (less than half of the times)
3. Sometimes (about half of the times)
4. Often (more than half of the times)
5. Almost every time/always
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